Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898917 | 0.88 | ALDH1A1 (0.48) | SLC22A12SLC22A6SLC22A8POLBKMT2A | |
| SCHEMBL4899865 | 0.88 | TDP1 (0.52) | SLC22A12SLC22A6SLC22A8POLBKMT2A | |
| SCHEMBL4901486 | 0.87 | SLC22A12 (0.48) | SLC22A12SLC22A6SLC22A8POLBKMT2A | |
| SCHEMBL4891308 | 0.86 | KMT2A (0.45) | SLC22A12SLC22A6SLC22A8POLBKMT2A | |
| SCHEMBL4895701 | 0.85 | KMT2A (0.53) | SLC22A12SLC22A6SLC22A8POLBKMT2A | |
| SCHEMBL4892147 | 0.82 | MAPT (0.50) | SLC22A12SLC22A6SLC22A8POLBKMT2A | |
| SCHEMBL4892266 | 0.82 | POLB (0.57) | SLC22A12SLC22A6SLC22A8POLB | |
| SCHEMBL4902073 | 0.82 | POLB (0.51) | SLC22A12SLC22A6SLC22A8POLB | |
| SCHEMBL4901031 | 0.80 | SLC22A12 (0.47) | SLC22A12SLC22A6SLC22A8POLBTDP1 | |
| SCHEMBL4901883 | 0.80 | SLC22A12 (0.49) | SLC22A12SLC22A6SLC22A8POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | claimed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | claimed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | claimed |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | NOD1, NLRP3, SLC10A1 | SLC22A12 446/4885SLC22A6 521/4885SLC22A8 216/4885 |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | NUDT1, NOD1, SLC28A1 | SLC22A12 260/4885SLC22A6 375/4885SLC22A8 222/4885 |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | NOD1, XDH, URB2 | SLC22A12 371/4885SLC22A6 285/4885SLC22A8 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.